EOLS on Nasdaq
Evolus, Inc.
American pharmaceutical preparations company based in Newport Beach2
In its 2026 annual report the company says: “We also operate in a very competitive and rapidly changing environment.”5 Its shares trade on Nasdaq under the symbol EOLS.2
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with Ironwood Pharmaceuticals, RIGEL PHARMACEUTICALS INC or Xeris Biopharma Holdings, Inc., or pick any stock.
- TickerEOLS on Nasdaq2
- IndustryPharmaceutical Preparations2
- HeadquartersNewport Beach, United States2
- Incorporated inDE3
- Business address520 Newport Center Drive, Suite 1200, Newport Beach, Ca 926603
- Filer categoryAccelerated filer3
- Legal formCorporation2
- LEI549300VYQRYBQOT8V4192
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered addressc/o REGISTERED AGENT SOLUTIONS, INC., 838 WALKER ROAD SUITE 21-2, 19904 Dover, United States2
- Registered withDivision of Corporations, Department of State, 52398912
See how the biggest companies compare on our leaderboards
You should carefully consider these risks, as well as the additional risks described in other documents we file with the U.S. Securities and Exchange Commission (“SEC”) in the future, including subsequent Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, which may from time to time amend, supplement or supersede the risks and uncertainties we disclose. We also operate in a very competitive and rapidly changing environment. New risks emerge from time to time and it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements.5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
66.3%Gross margin6
-11.0%Operating margin6
-17.4%Net margin6
11.6%Revenue growth, 20256
-$45.7MFree cash flow6
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Product brought in 99% of the revenue Evolus, Inc. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Product | $199.7M | $264.3M | $295.0M |
| Service | $2.4M | $2.0M | $2.2M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue31¢$100.1M
- Selling, general and admin69¢$220.8M
- Income tax0¢$677.0K
Out of $297.2M in revenue.6 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenues | $297.2M | $266.3M | $202.1M |
| Cost of goods sold | $100.1M | $84.0M | $64.5M |
| Gross profit | $197.1M | $182.3M | $137.6M |
| Selling, general and administrative | $220.8M | $198.0M | $164.9M |
| Research and development | $9.6M | $9.2M | $6.6M |
| In-process research and development | $0 | $0 | $8.9M |
| Revaluation of contingent royalty obligation payable to Evolus Founders | -$6.4M | $7.2M | $4.3M |
| Depreciation and amortization | $4.3M | $2.3M | $2.2M |
| Restructuring costs | $1.4M | $0 | $0 |
| Total operating expenses | $229.8M | $216.7M | $186.8M |
| Loss from operations | -$32.7M | -$34.4M | -$49.2M |
| Interest income | $1.9M | $3.3M | $860.0K |
| Interest expense | -$19.7M | -$18.7M | -$13.8M |
| Other income (expense), net | -$539.0K | $127.0K | $696.0K |
| Loss before income taxes | -$51.0M | -$49.8M | -$61.5M |
| Income tax expense | -$677.0K | -$664.0K | -$176.0K |
| Net loss | -$51.6M | -$50.4M | -$61.7M |
| Currency translation adjustment | $749.0K | -$478.0K | -$90.0K |
| Comprehensive loss | -$50.9M | -$50.9M | -$61.8M |
| Net loss per share, basic (in dollars per share) | -$0.80 | -$0.81 | -$1.08 |
| Net loss per share, diluted (in dollars per share) | -$0.80 | -$0.81 | -$1.08 |
| Weighted-average shares outstanding used to compute basic net loss per share (in shares) | 64.5M shares | 62.0M shares | 56.9M shares |
| Weighted-average shares outstanding used to compute diluted net loss per share (in shares) | 64.5M shares | 62.0M shares | 56.9M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $53.8M | $87.0M | ||
| Accounts receivable, net | $54.7M | $47.7M | ||
| Inventories | $27.0M | $12.2M | ||
| Prepaid expenses | $3.8M | $3.3M | ||
| Other current assets | $3.7M | $1.2M | ||
| Total current assets | $142.9M | $151.3M | ||
| Property and equipment, net | $5.4M | $3.2M | ||
| Operating lease right-of-use assets | $7.1M | $7.2M | ||
| Intangible assets, net | $48.0M | $48.8M | ||
| Goodwill | $21.2M | $21.2M | ||
| Other assets | $1.2M | $858.0K | ||
| Total assets | $225.9M | $232.6M | ||
| Accounts payable | $23.4M | $9.2M | ||
| Accrued expenses | $35.6M | $40.8M | ||
| Current portion of operating lease liabilities | $2.5M | $1.7M | ||
| Current portion of contingent royalty obligation payable to Evolus Founders | $12.5M | $11.2M | ||
| Current portion of contingent milestone payment | $1.3M | $0 | ||
| Total current liabilities | $75.3M | $63.0M | ||
| Long-term portion of operating lease liabilities | $6.4M | $6.8M | ||
| Long-term portion of contingent royalty obligation payable to Evolus Founders | $19.7M | $33.5M | ||
| Long-term portion of term loan, net of discount and issuance costs | $146.1M | $121.5M | ||
| Long-term portion of contingent milestone payment | $1.5M | $2.3M | ||
| Deferred tax liability | $28.0K | $6.0K | ||
| Total liabilities | $249.0M | $227.0M | ||
| Preferred Stock, $0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2025 and 2024, respectively | $0 | $0 | ||
| Common Stock, $0.00001 par value; 100,000,000 shares authorized; 65,008,183 and 63,497,548 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $1.0K | $1.0K | ||
| Additional paid-in capital | $638.1M | $615.8M | ||
| Accumulated other comprehensive loss | -$156.0K | -$905.0K | ||
| Accumulated deficit | -$661.0M | -$609.4M | ||
| Total stockholders equity (deficit) | -$23.1M | $5.5M | -$20.7M | $18.5M |
| Total liabilities and stockholders equity (deficit) | $225.9M | $232.6M | ||
| Common stock, shares, issued (in shares) | 65.0M shares | 63.5M shares | ||
| Common stock, shares, outstanding (in shares) | 65.0M shares | 63.5M shares | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $53.8M | $87.0M | ||
| Accounts receivable, net | $54.7M | $47.7M | ||
| Inventories | $27.0M | $12.2M | ||
| Prepaid expenses | $3.8M | $3.3M | ||
| Other current assets | $3.7M | $1.2M | ||
| Total current assets | $142.9M | $151.3M | ||
| Property and equipment, net | $5.4M | $3.2M | ||
| Operating lease right-of-use assets | $7.1M | $7.2M | ||
| Intangible assets, net | $48.0M | $48.8M | ||
| Goodwill | $21.2M | $21.2M | ||
| Other assets | $1.2M | $858.0K | ||
| Total assets | $225.9M | $232.6M | ||
| Accounts payable | $23.4M | $9.2M | ||
| Accrued expenses | $35.6M | $40.8M | ||
| Current portion of operating lease liabilities | $2.5M | $1.7M | ||
| Current portion of contingent royalty obligation payable to Evolus Founders | $12.5M | $11.2M | ||
| Current portion of contingent milestone payment | $1.3M | $0 | ||
| Total current liabilities | $75.3M | $63.0M | ||
| Long-term portion of operating lease liabilities | $6.4M | $6.8M | ||
| Long-term portion of contingent royalty obligation payable to Evolus Founders | $19.7M | $33.5M | ||
| Long-term portion of term loan, net of discount and issuance costs | $146.1M | $121.5M | ||
| Long-term portion of contingent milestone payment | $1.5M | $2.3M | ||
| Deferred tax liability | $28.0K | $6.0K | ||
| Total liabilities | $249.0M | $227.0M | ||
| Preferred Stock, $0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2025 and 2024, respectively | $0 | $0 | ||
| Common Stock, $0.00001 par value; 100,000,000 shares authorized; 65,008,183 and 63,497,548 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $1.0K | $1.0K | ||
| Additional paid-in capital | $638.1M | $615.8M | ||
| Accumulated other comprehensive loss | -$156.0K | -$905.0K | ||
| Accumulated deficit | -$661.0M | -$609.4M | ||
| Total stockholders equity (deficit) | -$23.1M | $5.5M | -$20.7M | $18.5M |
| Total liabilities and stockholders equity (deficit) | $225.9M | $232.6M | ||
| Common stock, shares, issued (in shares) | 65.0M shares | 63.5M shares | ||
| Common stock, shares, outstanding (in shares) | 65.0M shares | 63.5M shares | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$51.6M | -$50.4M | -$61.7M |
| Depreciation and amortization | $7.5M | $5.3M | $5.1M |
| Stock-based compensation | $20.7M | $22.3M | $16.5M |
| Provision for credit losses and inventory | $6.5M | $2.4M | $1.4M |
| Amortization of operating lease right-of-use assets | $1.2M | $723.0K | $734.0K |
| Amortization of debt discount and issuance costs | $1.3M | $1.1M | $1.1M |
| Deferred income taxes | $21.0K | -$21.0K | $5.0K |
| Revaluation of contingent royalty obligation payable to Evolus Founders | -$6.4M | $7.2M | $4.3M |
| Non-cash in-process research and development expense | $0 | $0 | $4.4M |
| Other adjustments to operating activities | $967.0K | $36.0K | $0 |
| Inventories | -$11.1M | $3.3M | $4.2M |
| Accounts receivable | -$11.5M | -$19.6M | -$9.5M |
| Prepaid expenses | -$355.0K | $2.4M | -$1.8M |
| Accounts payable | $10.1M | $391.0K | -$1.0M |
| Accrued expenses | -$6.4M | $7.0M | $9.0M |
| Accrued litigation settlement | $0 | $0 | -$5.0M |
| Operating lease liabilities | -$758.0K | -$716.0K | -$907.0K |
| Other operating assets | -$2.5M | $706.0K | -$864.0K |
| Net cash used in operating activities | -$42.3M | -$18.0M | -$34.0M |
| Purchases of property and equipment | -$3.4M | -$1.5M | -$473.0K |
| Additions to capitalized software | -$5.0M | -$3.4M | -$1.2M |
| Net cash used in investing activities | -$8.5M | -$4.8M | -$1.6M |
| Payment of contingent royalty obligation to Evolus Founders | -$6.2M | -$7.4M | -$5.5M |
| Proceeds from issuance and modification of debt instruments | $25.0M | $0 | $50.0M |
| Payments for debt modification fees and debt issuance costs | -$2.6M | $0 | -$46.0K |
| Proceeds from follow-on offering | $0 | $51.2M | $0 |
| Payments for offering costs | $0 | -$248.0K | $0 |
| Issuance of common stock in connection with incentive equity plan | $1.2M | $4.9M | $231.0K |
| Payment of finance lease obligations | -$15.0K | $0 | $0 |
| Tax withholding paid on behalf of employees for net share settlement | $0 | -$990.0K | -$7.0K |
| Net cash provided by financing activities | $17.3M | $47.4M | $44.6M |
| Effect of exchange rates on cash and cash equivalents | $254.0K | -$478.0K | -$90.0K |
| Net increase (decrease) in cash and cash equivalents | -$33.1M | $24.1M | $8.9M |
| Cash paid for interest | $14.8M | $17.5M | $12.7M |
| Cash paid for income taxes | $1.2M | $235.0K | $117.0K |
| Capital expenditures included in accounts payable and accrued expenses | $695.0K | $252.0K | $43.0K |
| Issuance of common stock in connection with Symatese Europe Agreement | $0 | $0 | $1.5M |
No quarter-by-quarter statement was filed.
Corporate structure
Evolus, Inc. sits at the top of its group. 6 entities, 6 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Evolus, Inc.
- Soleus Capital Master Fund, L.P. Filed SCHEDULE 13G on Evolus, Inc., latest Aug 31, 2026
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on Evolus, Inc., latest Mar 26, 2026 (2 filings since Feb 13, 2024)
- Caligan Partners LP Filed SCHEDULE 13G/A on Evolus, Inc., latest Feb 17, 2026 (3 filings since Aug 14, 2025)
- TANG CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G/A on Evolus, Inc., latest Feb 17, 2026 (3 filings since Nov 14, 2024)
- Timothy P. Lynch Filed SCHEDULE 13G/A on Evolus, Inc., latest Feb 17, 2026 (3 filings since Aug 18, 2025)
- Nantahala Capital Management, LLC Filed SCHEDULE 13G/A on Evolus, Inc., latest Nov 14, 2025 (4 filings since Feb 14, 2024)
- PERCEPTIVE ADVISORS LLC Filed SCHEDULE 13G/A on Evolus, Inc., latest Aug 14, 2025 (5 filings since Nov 27, 2023)
- Medytox Inc. Filed SCHEDULE 13G/A on Evolus, Inc., latest Feb 6, 2025 (4 filings since Feb 9, 2022)
- BlackRock Filed SCHEDULE 13G/A on Evolus, Inc., latest Feb 5, 2025 (2 filings since Jan 29, 2024)
- Stonepine Capital Management, LLC Filed SC 13G/A on Evolus, Inc., latest Nov 13, 2024 (3 filings since Jun 16, 2023)
- TANG CAPITAL PARTNERS LP Filed SC 13G/A on Evolus, Inc., latest Feb 14, 2024 (2 filings since Feb 21, 2023)
- FIRST MANHATTAN CO. LLC. Filed SC 13G/A on Evolus, Inc., latest Feb 12, 2024 (3 filings since Feb 15, 2022)
- Evolus, Inc. Newport Beach, California, United States
- Evolus Australia Pty Ltd Subsidiary · Australia
- Evolus International Ltd. Subsidiary · United Kingdom
- Evolus New Zealand Limited Subsidiary · New Zealand
- Evolus Pharma BV Subsidiary · Netherlands
- Evolus-Pharma Spain SL Subsidiary · Spain
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Evolus, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $10.1M6 Dec 31, 2025 | $6.7M6 Dec 31, 2024 | +50.2% |
| Accumulated depreciation | $4.8M6 Dec 31, 2025 | $3.5M6 Dec 31, 2024 | +35.1% |
| Property and equipment, net | $5.4M6 Dec 31, 2025 | $3.2M6 Dec 31, 2024 | +66.7% |
| Operating-lease assets (leased space) | $7.1M6 Dec 31, 2025 | $7.2M6 Dec 31, 2024 | −0.7% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $53.8M6 Dec 31, 2025 | $87.0M6 Dec 31, 2024 | −38.1% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $21.2M6 Dec 31, 2025 | $21.2M6 Dec 31, 2024 | 0% |
| Intangible assets, net (excluding goodwill) | $48.0M6 Dec 31, 2025 | $48.8M6 Dec 31, 2024 | −1.5% |
| Finite-lived intangibles, gross | $81.7M6 Dec 31, 2025 | $76.1M6 Dec 31, 2024 | +7.3% |
| Accumulated amortization | $33.6M6 Dec 31, 2025 | $27.4M6 Dec 31, 2024 | +22.9% |
| Finite-lived intangibles, net | $48.0M6 Dec 31, 2025 | $48.8M6 Dec 31, 2024 | −1.5% |
Inventory
Properties, in its own words
Our corporate headquarters is located at 520 Newport Center Drive, Suite 1200, Newport Beach, CA 92660, in a facility that we lease, encompassing in aggregate approximately 30,716 square feet of space. On July 27, 2023, we entered into an amendment to the existing lease agreement for our corporate headquarters for additional office space of approximately 8,333 square feet of space (the “Amended Lease Agreement”). On October 16, 2024, we entered into the Second Amendment to the Lease Agreement (the “Second Lease Amendment” and, with the Amended Lease Agreement, the “Lease Agreement”) to lease additional office space for our corporate headquarters. The lease term for the Second Lease Amendment commenced beginning in October 2025. The Lease Agreement expires on January 31, 2030. With the additional office space, we believe our facilities are sufficient for our current needs. When the Lease Agreement expires, we may exercise our renewal option or
look for additional or alternative space for our operations, and we believe that suitable additional or alternative space will be available in the future on commercially reasonable terms.
Item 2 of the 10-K filed Mar 3, 2026.5
Leadership
Who has led Evolus, Inc., and when. Pick a name to see everywhere that person has worked.
Chief financial officer
Chief operating officer
20202025
- Chief financial officerTatjana Mitchell Oct 9, 2025 to now15
- Chief financial officerSandra Beaver Sep 6, 2022 to Oct 9, 202516
- Chief operating officerJ. Christopher Marmo Feb 7, 2018 to Feb 7, 201817
Board members and other officers (17)
- Chief Marketing OfficerTomoko Yamagishi-Dressler Aug 23, 2023 to now18
- Chief Marketing OfficerCrystal Muilenburg Mar 1, 2021 to Mar 10, 202219
- OfficerMurthy Simhambhatla V. Feb 7, 2018 to Feb 7, 201820
- Chief Medical OfficerRui Avelar Feb 7, 2018 to now21
- OfficerDavid Moatazedi May 8, 2018 to now22
- OfficerLauren P. Silvernail May 31, 2018 to May 18, 202223
- Board memberAlbert G. White Iii. Jul 3, 2024 to now24
- Board memberKarah Herdman Parschauer Jul 17, 2019 to now25
- Board memberPeter Farrell Jul 17, 2019 to Jan 31, 202326
- Board memberBosun Hau Feb 7, 2018 to Jan 24, 202027
- Board memberKristine Romine Feb 7, 2018 to Jan 24, 202028
- Board memberMurthy Simhambhatla V. Feb 7, 2018 to Feb 7, 201820
- Board memberRobert Hayman Feb 7, 2018 to Feb 9, 202429
- Board memberSimone Blank Feb 7, 2018 to now30
- Board memberVikram Malik Feb 7, 2018 to now31
- Board memberDavid N. Gill Feb 12, 2018 to now32
- Board memberDavid Moatazedi May 8, 2018 to now22
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- Evolus Australia Pty Ltd Australia4
- Evolus GmbH Germany4
- Evolus International Ltd. United Kingdom4
- Evolus New Zealand Limited New Zealand4
- Evolus Pharma BV Netherlands4
- Evolus Pharma Limited Ireland4
- Evolus-Pharma Spain SL Spain4
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Timeline
- Aug 5, 20268-K Results of operations33
- Aug 4, 20268-K Entered a material agreement; Regulation FD disclosure34
- Jul 8, 20268-K Entered a material agreement; Regulation FD disclosure35
- Jun 12, 20268-K Shareholder vote36
- May 4, 20268-K Results of operations; Regulation FD disclosure37
- Mar 13, 20268-K Executive or director change38
- Mar 3, 20268-K Entered a material agreement; Results of operations; New debt or obligation39
- Jan 9, 20268-K Results of operations40
- Nov 5, 20258-K Results of operations41
- Sep 8, 20258-K Executive or director change; Regulation FD disclosure42
- Aug 5, 20258-K Results of operations; Executive or director change43
- Jun 6, 20258-K Executive or director change; Shareholder vote44
- Nov 9, 2012Founded Evolus, Inc. is founded2
Calendar
Coming up
- Nov 4, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.20) a share, on Nov 5, 2025.45
When it reported results
- Aug 5, 2026Reported quarterly or annual results33
- May 4, 2026Reported quarterly or annual results37
- Mar 3, 2026Reported quarterly or annual results39
- Jan 9, 2026Reported quarterly or annual results40
- Nov 5, 2025Reported quarterly or annual results41
- Aug 5, 2025Reported quarterly or annual results43
- May 7, 2025Reported quarterly or annual results46
- Mar 4, 2025Reported quarterly or annual results47
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
291 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 48 major events, 132 insider forms, 41 large holders, 50 other. The latest 20:
- Sep 4, 20264 EDGAR
- Sep 2, 2026144 EDGAR
- Aug 31, 2026SCHEDULE 13G EDGAR
- Aug 5, 202610-Q EDGAR
- Aug 5, 20268-K EDGAR
- Aug 4, 20268-K EDGAR
- Jul 8, 20268-K EDGAR
- Jun 12, 2026EFFECT EDGAR
- Jun 12, 20268-K EDGAR
- Jun 10, 2026CORRESP EDGAR
- Jun 10, 2026UPLOAD EDGAR
- Jun 5, 2026S-3 EDGAR
- May 4, 202610-Q EDGAR
- May 4, 20268-K EDGAR
- Apr 29, 2026DEFA14A EDGAR
- Apr 29, 2026DEF 14A EDGAR
- Apr 29, 2026ARS EDGAR
- Mar 26, 2026SCHEDULE 13G/A EDGAR
- Mar 20, 20264 EDGAR
- Mar 20, 20264 EDGAR
The 291 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
81 open-market trades by officers, directors and large owners since October 2021: 9 buys and 72 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | MOATAZEDI DAVIDSee Remarks | Sale | 105,108 | $9.04 | $950.2K | Form 4 |
| Mar 20, 2026 | Avelar RuiSee Remarks | Sale | 3,119 | $4.75 | $14.8K | Form 4 |
| Mar 20, 2026 | MOATAZEDI DAVIDSee Remarks | Sale | 13,669 | $4.75 | $64.9K | Form 4 |
| Mar 17, 2026 | MOATAZEDI DAVIDSee Remarks | Sale | 116,720 | $4.89 | $570.8K | Form 4 |
| Mar 17, 2026 | Avelar RuiSee Remarks | Sale | 29,996 | $4.89 | $146.7K | Form 4 |
| Dec 22, 2025 | MOATAZEDI DAVIDSee Remarks | Sale | 10,539 | $7.15 | $75.4K | Form 4 |
| Dec 22, 2025 | Avelar RuiSee Remarks | Sale | 2,261 | $7.15 | $16.2K | Form 4 |
| Aug 22, 2025 | Yamagishi-Dressler TomokoChief Marketing Officer | Sale | 5,722 | $7.51 | $43.0K | Form 4 |
| Aug 15, 2025 | Stewart BradyDirector | Buy | 30,000 | $6.82 | $204.6K | Form 4 |
| Jun 16, 2025 | MOATAZEDI DAVIDSee Remarks | Sale | 16,582 | $9.89 | $164.0K | Form 4 |
| Jun 13, 2025 | MOATAZEDI DAVIDSee Remarks | Sale | 111,323 | $10.05 | $1.1M | Form 4 |
| Jun 9, 2025 | White Albert G IIIDirector | Buy | 20,000 | $9.45 | $189.0K | Form 4 |
| May 13, 2025 | Beaver SandraChief Financial Officer | Sale | 6,494 | $10.02 | $65.1K | Form 4 |
| May 12, 2025 | Avelar RuiSee Remarks | Sale | 3,385 | $9.87 | $33.4K | Form 4 |
| May 12, 2025 | MOATAZEDI DAVIDSee Remarks | Sale | 15,787 | $9.87 | $155.8K | Form 4 |
| Mar 27, 2025 | MOATAZEDI DAVIDSee Remarks | Sale | 6,251 | $12.40 | $77.5K | Form 4 |
| Mar 18, 2025 | Avelar RuiSee Remarks | Sale | 27,904 | $13.26 | $370.0K | Form 4 |
| Mar 18, 2025 | Beaver SandraChief Financial Officer | Sale | 8,996 | $13.26 | $119.3K | Form 4 |
| Mar 18, 2025 | Yamagishi-Dressler TomokoChief Marketing Officer | Sale | 4,536 | $13.26 | $60.1K | Form 4 |
| Mar 18, 2025 | MOATAZEDI DAVIDSee Remarks | Sale | 103,376 | $13.26 | $1.4M | Form 4 |
All 81 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Soleus Capital Master Fund, L.P.SCHEDULE 13G, 1 filing Aug 31, 202648
- VANGUARD GROUP INCSCHEDULE 13G/A, 2 filings Feb 13, 2024 to Mar 26, 202649
- Caligan Partners LPSCHEDULE 13G/A, 3 filings Aug 14, 2025 to Feb 17, 202650
- TANG CAPITAL MANAGEMENT LLCSCHEDULE 13G/A, 3 filings Nov 14, 2024 to Feb 17, 202651
- Timothy P. LynchSCHEDULE 13G/A, 3 filings Aug 18, 2025 to Feb 17, 202652
- Nantahala Capital Management, LLCSCHEDULE 13G/A, 4 filings Feb 14, 2024 to Nov 14, 202553
- PERCEPTIVE ADVISORS LLCSCHEDULE 13G/A, 5 filings Nov 27, 2023 to Aug 14, 202554
- Medytox Inc.SCHEDULE 13G/A, 4 filings Feb 9, 2022 to Feb 6, 202555
- BlackRockSCHEDULE 13G/A, 2 filings Jan 29, 2024 to Feb 5, 202556
- Stonepine Capital Management, LLCSC 13G/A, 3 filings Jun 16, 2023 to Nov 13, 202457
- TANG CAPITAL PARTNERS LPSC 13G/A, 2 filings Feb 21, 2023 to Feb 14, 202458
- FIRST MANHATTAN CO. LLC.SC 13G/A, 3 filings Feb 15, 2022 to Feb 12, 202459
- James E. FlynnSC 13G/A, 3 filings Jun 6, 2022 to Oct 4, 202360
- Alphaeon 1 LLCSC 13D/A, 1 filing Aug 14, 202361
- MILLENNIUM MANAGEMENT LLCSC 13G/A, 2 filings Feb 15, 2023 to May 9, 202362
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | David Moatazedi | 48 | $775.0K | $6.4M63 |
| 2025 | Tatjana Mitchell | 48 | $154.2K | $3.2M63 |
| 2025 | Sandra Beaver | $231.9K | $1.7M63 | |
| 2025 | Rui AvelarM.D. | 64 | $545.4K | $1.7M63 |
| 2025 | Tomoko Yamagishi-Dressler | $285.2K | $1.6M63 | |
| 2024 | President and Chief Executive Officer | $743.8K | $7.0M63 | |
| 2024 | Chief Medical Officer and Head of Research and Development | $515.7K | $2.9M63 | |
| 2024 | Former Chief Financial Officer | $477.6K | $1.9M63 | |
| 2024 | Former Chief Marketing Officer | $429.5K | $1.5M63 | |
| 2023 | President and Chief Executive Officer | $687.5K | $11.2M63 | |
| 2023 | Chief Medical Officer and Head of Research and Development | $487.8K | $2.9M63 | |
| 2023 | Former Chief Financial Officer | $437.5K | $2.5M63 | |
| 2023 | Former Chief Marketing Officer | $151.3K | $1.7M63 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 11,204,042 | $77.8M | 2.4% | +4,827,185 |
| BlackRock, Inc. | 4,840,828 | $33.6M | 0.0% | +550,445 |
| Braidwell LP | 3,155,209 | $21.9M | 0.8% | +50,000 |
| Frazier Life Sciences Management, L.P. | 2,630,665 | $18.3M | 0.4% | No change |
| Perceptive Advisors LLC | 2,459,285 | $17.1M | 0.3% | +1,172,423 |
| Vanguard Capital Management LLC | 2,362,893 | $16.4M | 0.0% | −107,515 |
| Assenagon Asset Management S.A. | 1,816,360 | $12.6M | 0.0% | +1,218,215 |
| Millennium Management LLC | 1,787,929 | $12.4M | 0.0% | +326,770 |
| State Street Corp | 1,697,294 | $11.8M | 0.0% | +376,504 |
| Geode Capital Management, LLC | 1,608,394 | $11.2M | 0.0% | +227,056 |
| Stonepine Capital Management, LLC | 1,590,162 | $11.0M | 8.4% | −168,929 |
| Point72 Asset Management, L.P. | 1,508,518 | $10.5M | 0.0% | New |
| Pinnacle Associates Ltd | 1,487,264 | $10.3M | 0.1% | +328,369 |
| Armistice Capital, LLC | 1,436,000 | $10.0M | 0.3% | +40,000 |
| Rice Hall James & Associates, LLC | 1,289,888 | $9.0M | 0.4% | +35,069 |
| AWH Capital, L.P. | 1,250,000 | $8.7M | 3.0% | +625,000 |
| Goldman Sachs Group Inc | 1,219,419 | $8.5M | 0.0% | +133,021 |
| Soleus Capital Management, L.P. | 822,428 | $5.7M | 0.2% | −1,422,932 |
| Soviero Asset Management, LP | 770,000 | $5.3M | 2.6% | +89,627 |
| UBS Group AG | 752,679 | $5.2M | 0.0% | −202 |
| Vanguard Portfolio Management LLC | 545,702 | $3.8M | 0.0% | +68,625 |
| Charles Schwab Investment Management Inc | 530,843 | $3.7M | 0.0% | +15,327 |
| Citadel Advisors LLC | 506,354 | $3.5M | 0.0% | −190,275 |
| Northern Trust Corp | 497,018 | $3.4M | 0.0% | +24,675 |
| Vanguard Fiduciary Trust Co | 456,183 | $3.2M | 0.0% | +31,525 |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Evolus, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGAREvolus, Inc.1
- CIK0001570562
- Employer ID (EIN)46-13856145
- Filer statusAccelerated filer not an emerging growth company; not a smaller reporting company; not a shell company5
- Incorporated inDelaware5
- Fiscal year endsDecember 311
- Industry code (SIC)2834 Pharmaceutical Preparations1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address520 Newport Center Drive, Suite 1200, Newport Beach, CA 926601
- Phone(949) 284-45551
- Shares outstanding66,050,440 as of Jul 31, 202613
- Public float$560.4M as of Jun 30, 20255
- AuditorErnst & Young LLP, Irvine, California PCAOB ID 42; it also attests to the company’s internal control over financial reporting5
- On EDGAR sinceFeb 27, 20131
- Filings555 in all: 4 (224), 8-K (99), 10-Q (26), 3 (23), SC 13G/A (19), SC 13G (15), CORRESP (14), SCHEDULE 13G/A (13)1
All 38 form types
UPLOAD (13), 144 (12), S-8 (12), 10-K (9), DEF 14A (8), DEFA14A (8), 424B5 (7), 4/A (5), EFFECT (5), 424B4 (4), ARS (4), SCHEDULE 13G (4), S-1/A (3), S-3 (3), S-3/A (3), SC 13D/A (3), D (2), DRS (2), DRS/A (2), DRSLTR (2), S-1 (2), 10-K/A (1), 10-Q/A (1), 8-A12B (1), CERT (1), CT ORDER (1), FWP (1), PRE 14A (1), S-3MEF (1), SC 13D (1)
- Latest filingsAnnual report (10-K) Mar 3, 2026
Quarterly report (10-Q) Aug 5, 2026
Proxy statement (DEF 14A) Apr 29, 2026
Latest 8-K (8-K) Aug 5, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, $0.00001 par value per share | EOLS | The Nasdaq Stock Market LLC |
From the cover page of the 10-K filed Mar 3, 2026 (Section 12(b) of the Exchange Act).5
Risk factors and legal proceedings
The risks Evolus, Inc. names in Item 1A of its 10-K filed Mar 3, 2026: 52 risks under these headings, as written.5
- Risks Related to Our Business and Strategy
- Our products face significant competition and our failure to effectively compete may prevent us from achieving significant market penetration and expansion.
- Our products may fail to achieve the broad degree of aesthetic practitioner adoption and use or consumer demand necessary for continued commercial success.
- Our products rely on consumer discretionary spending and the purchasing decisions of our customers, both of which are sensitive to difficult to predict global economic conditions, including the imposition of tariffs, or changes in consumer or customer sentiment.
- We are reliant on Symatese to achieve and maintain regulatory approval for the Evolysse™ product line in the United States. Failure to obtain approval, maintain approval, or obtain approval on our estimated time frame for additional Evolysse™ products would negatively affect our ability to sell these products.
- We may require additional financing to fund our future operations or execute corporate development activities, and a failure to obtain additional capital when so needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our operations.
- If we or our counterparties do not comply with the terms of our settlement agreement with Medytox, we may face litigation or lose our ability to market and sell Jeuveau®, which would materially and adversely affect our ability to carry out our business, our financial condition and ability to continue as a going concern.
- The terms of the Medytox Settlement Agreements will reduce our profitability until the royalty obligations expire, and may affect the extent of any discounts we may offer to our customers.
- Our ability to market our products is limited to their indicated uses, and if we want to expand the indications for which we market our products, we will need to obtain additional regulatory approvals, which will be expensive and may not be granted.
- We rely on our digital technology and applications and our business and operations could suffer in the event of information system failures or a cybersecurity incident.
- Our use of, or failure to effectively and responsibly utilize, emerging technologies, including artificial intelligence, could materially adversely affect our business and financial results.
- Failure to comply with confidentiality and data privacy obligations could have a material adverse effect on our business.
The other 41 risks
- Jeuveau® or any other product candidate for which we seek approval as a biologic may face competition sooner than anticipated.
- If we are found to have improperly promoted off-label uses, or if customers misuse our products or use our products off-label, we may become subject to prohibitions on the sale or marketing of our products, significant fines, penalties, sanctions, or product liability claims, and our image and reputation within the industry and marketplace could be harmed.
- Our products may cause serious or undesirable side effects or possess other unexpected properties that could delay or prevent their regulatory approval, limit the commercial profile of approved labeling, result in post-approval regulatory action or in product liability lawsuits.
- Our failure to successfully in-license, acquire, develop and market additional product candidates or approved products would impair our ability to grow our business.
- Our international operations will expose us to risks, and failure to manage these risks may adversely affect our operating results and financial condition.
- Fluctuations in currency exchange rates may negatively affect our financial condition and results of operations.
- If we fail to attract and keep senior management and key personnel, we may be unable to market and sell our products successfully, or any future products we develop.
- Our strategy of focusing exclusively on the cash-pay healthcare market may limit our ability to increase sales or achieve profitability.
- We may need to increase the size of our organization, including our sales and marketing capabilities, in order to further market and sell our products and we may experience difficulties in managing this growth.
- Our business involves the use of hazardous materials, and we and our third-party manufacturer and supplier must comply with environmental laws and regulations, which can be expensive and restrict how we do business.
- We may use third-party collaborators to help us develop, validate or commercialize any new products, and our ability to commercialize such products could be impaired or delayed if these collaborations are unsuccessful.
- Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.
- Increases in interest rates would increase the cost of servicing our debt and could reduce our profitability and limit our cash available to fund our growth strategy.
- Risks Related to Our Relationship with Our Licensors
- We rely on the Daewoong Agreement, the Symatese U.S. Agreement and the Symatese Europe Agreement and any termination or loss of significant rights, including exclusivity, under these agreements would materially and adversely affect our business.
- We currently rely solely on Daewoong to manufacture Jeuveau®, and on Symatese to manufacture Evolysse™ and as such, any production or other problems with either licensor could adversely affect us.
- We forecast the demand for commercial quantities of our products, and if our forecasts are inaccurate, we may experience delays in shipments, increased inventory costs or inventory levels, and reduced cash flow.
- Risks Related to Intellectual Property
- Third-party claims of intellectual property infringement may prevent or delay our commercialization efforts and interrupt our supply of products.
- If we or any of our current or future licensors, including Daewoong and Symatese, are unable to maintain, obtain or protect intellectual property rights related to our products, we may not be able to compete effectively in our market.
- We may become involved in lawsuits to protect or enforce our intellectual property or the patents and other intellectual property of our licensors, which could be expensive and time-consuming.
- We may not be able to protect our intellectual property rights throughout the world.
- If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
- We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.
- We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.
- If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
- Risks Related to Government Regulation
- Our business and products are subject to extensive government regulation.
- We may not obtain regulatory approval for the commercialization of any future product candidates.
- We are subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, limit or delay regulatory approval and subject us to penalties if we fail to comply with applicable regulatory requirements.
- If we fail to obtain regulatory approvals in foreign jurisdictions for our products or any future product candidates, we will be unable to market our products outside of the United States.
- Our products or any future products may cause or contribute to adverse medical events that we are required to report to regulatory agencies and if we fail to do so, we could be subject to sanctions that would materially harm our business.
- We may in the future be subject to various U.S. federal and state laws pertaining to health care fraud and abuse, including anti-kickback, self-referral, false claims and fraud laws, and any violations by us of such laws could result in fines or other penalties.
- Legislative or regulatory healthcare reforms in the United States and other countries may make it more difficult and costly for us to obtain regulatory clearance or approval of any future product candidates and to produce, market, and distribute our products after clearance or approval is obtained.
- Risks Related to Our Common Stock
- Derivative lawsuits have been filed against us and certain of our officers and directors, which could result in substantial costs and could divert management attention.
- The trading price of our common stock has been volatile, and purchasers of our common stock could incur substantial losses.
- Future sales of our common stock by us or the perception that such sales may occur, could depress the market price of our common stock.
- Anti-takeover provisions in our certificate of incorporation and bylaws, as well as Delaware law, could discourage a takeover.
- Our certificate of incorporation designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents.
- Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.
- General Risk Factors
- Our business could be negatively affected as a result of actions of activist stockholders, and such activism could impact the trading value of our securities.
- If securities or industry analysts publish unfavorable research about our business or decrease the frequency or cease to provide coverage of our company, our stock price and trading volume could decline.
- We have not paid dividends in the past and do not expect to pay dividends in the future, and any return on investment may be limited to the value of our stock.
- The requirements of being a public company may strain our resources, divert management’s attention and affect our ability to attract and retain executive management and qualified Board members.
Legal proceedings
We are and may become from time to time a party to various claims and lawsuits arising in the ordinary course of business, but we are not a party to any material legal proceeding required to be disclosed under Item 103 of Regulation S-K.
The opening of Item 3, Legal Proceedings.5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGAREvolus, Inc. filings on SEC EDGAR
- 2
- 3SEC EDGAREvolus, Inc. filings on SEC EDGAR
- 4
- 5
- 6SEC EDGAREvolus, Inc. 10-K for fiscal 2025
- 7SEC EDGAREvolus, Inc. 10-K for fiscal 2019
- 8SEC EDGAREvolus, Inc. 10-K for fiscal 2020
- 9SEC EDGAREvolus, Inc. 10-K for fiscal 2021
- 10SEC EDGAREvolus, Inc. 10-K for fiscal 2022
- 11SEC EDGAREvolus, Inc. 10-K for fiscal 2019
- 12SEC EDGAREvolus, Inc. 10-Q for fiscal 2026
- 13SEC EDGAREvolus, Inc. 10-Q for fiscal 2026
- 14SEC EDGAREvolus, Inc. 10-K for fiscal 2022
- 15
- 16
- 17
- 18
- 19
- 20SEC EDGARMurthy Simhambhatla V., Officer
- 21SEC EDGARRui Avelar, Chief Medical Officer
- 22SEC EDGARDavid Moatazedi, Officer
- 23SEC EDGARLauren P. Silvernail, Officer
- 24SEC EDGARAlbert G. White Iii., Board member
- 25
- 26SEC EDGARPeter Farrell, Board member
- 27SEC EDGARBosun Hau, Board member
- 28SEC EDGARKristine Romine, Board member
- 29SEC EDGARRobert Hayman, Board member
- 30SEC EDGARSimone Blank, Board member
- 31SEC EDGARVikram Malik, Board member
- 32SEC EDGARDavid N. Gill, Board member
- 33SEC EDGARResults of operations
- 34
- 35
- 36SEC EDGARShareholder vote
- 37
- 38SEC EDGARExecutive or director change
- 39
- 40SEC EDGARResults of operations
- 41SEC EDGARResults of operations
- 42
- 43
- 44
- 45NasdaqNasdaq calendar
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63